PATENT CLAIM ANALYSIS

Application Number: 15981892
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-02
Patent Classification: ["514", "300000"]

Abstract:
This invention is directed to selective androgen receptor degrader (SARD) compounds pharmaceutical compositions and uses thereof in treating early prostate cancer, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Claim (Index 21):
The method of  claim 19 , wherein said NTD binding site for the compound binds between amino acid 380 and amino acid 529.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 93.0
- Lexical Diversity: 1.56
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15222734', '15135334', '15331777', '15981636', '15923668']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.918139986417686
- 35 USC 102 Novelty (BERT): 0.6469860815946639
- Combined Prediction Score: 0.8910245959353837
- Mean Citation Score: 942.740778
- Max Citation Score: 977.20337
- Similarity Product: 586.6784517141061

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test